期刊
LEUKEMIA & LYMPHOMA
卷 61, 期 10, 页码 2375-2382出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2020.1772477
关键词
CLL; BTK inhibitor; ibrutinib; acalabrutinib; infection; immune system
资金
- Intramural Research Program of the NHLBI, NIH, Pharmacyclics LLC
- Abbvie company
- Acerta Pharma, a member of the Astra-Zeneca group
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006070, ZIAHL002346] Funding Source: NIH RePORTER
Immune dysregulation in chronic lymphocytic leukemia (CLL) contributes to a high rate of infections and morbidity. The Bruton tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib mark major breakthroughs in the treatment of CLL, however many patients require long-term therapy with these agents. Despite receiving effective therapy for CLL, patients on BTK inhibitors remain immunocompromised and at risk of infectious complications. We previously reported that treatment of CLL with ibrutinib leads to partial reconstitution of humoral immunity and fewer infections during the first two years of therapy. It is currently unclear whether the positive effects of ibrutinib on the immune system are sustained during long-term therapy. Acalabrutinib is a newer, more selective BTK inhibitor than ibrutinib; however a detailed evaluation of the immunologic impact of acalabrutinib therapy is lacking. Herein, utilizing two independent trials, we assessed the immunological effects and infectious risk of ibrutinib and acalabrutinib treatment in patients with CLL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据